Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 11/29 11:31:49 am
74.24 CHF   -0.64%
12:41pNOVARTIS : at ASH
PU
11/26Roche Shareholders Approve Deal to Buy Back Novartis' Stake in Swiss Drugmaker
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis may divest generic unit Sandoz as price pressures mount

10/26/2021 | 01:56am EST

* Says to update on Sandoz strategic review by end-2022

* Says options include "separation" or retaining the unit

* Lower prices drag Q3 Sandoz sales lower

* Forecast-beating Cosentyx, Entresto drive group sales growth

Oct 26 (Reuters) - Novartis has raised the prospect of divesting its generic drugs unit Sandoz after years of revamping the business, as price pressures mount in the off-patent drug sector.

"Novartis has commenced a strategic review of the Sandoz Division," the Swiss-based group said in statement alongside quarterly results in which it lifted its peak revenue estimate for its two best-selling pharmaceuticals.

Sandoz achieved sales of $9.7 billion last year, about 20 percent of the group's total, but Novartis on Tuesday warned it expected the unit's operating income to fall faster than previously expected this year.

"The review will explore all options, ranging from retaining the business to separation, in order to determine how to best maximize value for our shareholders," the statement said.

Novartis added it would have more to say on the review of Sandoz, which makes cheaper copies of drugs that have lost patent protection, by the end of next year.

"It's synergies versus freedom and the ability to allocate capital and all of these considerations will of course be undertaken now," Chief Executive Vas Narasimhan said in a media briefing.

He started setting up the generics business as an independent unit and slashing costs in early 2019, shortly after selling most of Sandoz's U.S. operations. Competitive pressures on prices, which have long been a burden, increased in the third quarter, with the U.S. market a particular challenge.

The company would not say whether rivals or financial investors might buy it, or whether Sandoz could be floated on the stock exchange.

Though the group's 2021 target for group earnings growth remained at a "mid-single digit" percentage rate, Novartis downgraded Sandoz's full-year outlook for operating income to a decline by a "mid to high teens” percentage rate," worse than the "low to midteens” seen previously.

CONSOLIDATION MODE

"Given the continued drag on Novartis growth from Sandoz, the announcement of a strategic review is likely to be well received," JP Morgan analysts said in a research note.

Novartis shares gained 0.9% to 77.70 Swiss francs, while the STOXX Europe 600 Health Care index edged up 0.2%.

The generic drugs industry has been in consolidation mode for years. The trend culminated in the creation of Viatris from the merger last year of Mylan and Pfizer's Upjohn unit, which expects up to $17.9 billion in revenue in 2021. It is worth close to $17 billion on the stock market.

Israel's Teva and Sandoz, with roughly $10 billion in annual generic drug sales each, are runners-up in the sector. Other players include Perrigo, Sun Pharma and Aurobindo.

Novartis reiterated that Sandoz will need to invest in the launch of a raft of "biosimilar" drugs, which are cheaper versions of complex biotech drugs that have lost patent protection.

The group's third-quarter operating profit, adjusted for special items, rose 10% to $4.47 billion, driven by better-than-expected sales of arthritis and psoriasis drug Cosentyx and heart failure treatment Entresto.

It increased its peak sales guidance for Cosentyx to at least $7 billion from a goal of at least $5 billion previously, and for Entresto to at least $5 billion, from at least $4 billion.

Third-quarter sales rose 6% to $13.03 billion, in line with the average analyst estimate compiled by Refinitiv, while core net income increased 10% to $3.83 billion versus a market consensus of $3.7 billion. (Reporting by Ludwig Burger; Editing by Michael Shields and David Holmes)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AUROBINDO PHARMA -3.49% 654.9 Delayed Quote.-26.35%
NOVARTIS AG -0.64% 74.24 Delayed Quote.-10.68%
SUN PHARMACEUTICAL INDUSTRIES LTD. -2.12% 751.05 Delayed Quote.29.53%
VIATRIS INC. -1.84% 12.52 Delayed Quote.-31.96%
All news about NOVARTIS AG
12:41pNOVARTIS : at ASH
PU
11/26Roche Shareholders Approve Deal to Buy Back Novartis' Stake in Swiss Drugmaker
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26Roche Shareholders OK $21 Billion Repurchase Deal With Novartis
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26NOVARTIS AG : Gets a Neutral rating from UBS
MD
11/24Novartis' Lung Cancer Therapy Receives South Korean Regulator's OK
MT
11/23EMEA MORNING BRIEFING : Stocks to Track Wall -2-
DJ
11/22Holmes defends beliefs in Theranos technology at her fraud trial
RE
11/22Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day..
MT
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 969 M - -
Net income 2021 13 172 M - -
Net Debt 2021 21 489 M - -
P/E ratio 2021 13,5x
Yield 2021 4,03%
Capitalization 181 B 181 B -
EV / Sales 2021 3,90x
EV / Sales 2022 3,66x
Nbr of Employees 108 000
Free-Float 85,7%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 80,94 $
Average target price 98,86 $
Spread / Average Target 22,1%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-10.68%181 102
JOHNSON & JOHNSON1.16%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049